TrialBlood2020

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.

John C Byrd et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.